<DOC>
	<DOC>NCT01138163</DOC>
	<brief_summary>The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.</brief_summary>
	<brief_title>Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Adults over age 18 years of age with a life expectancy of at least 3 months. Histologically or cytologically confirmed stage IIIB or stage IV non squamous nonsmallcell lung cancer (NSCLC) who have progressed after 1 chemotherapy regimen. Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST, Version 1.1) on crosssectional imaging that is at least 2 cm in longest diameter. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2. Adequate hematologic, renal, and hepatic function. PT/INR ≤ 1.5 × ULN; aPTT time ≤ 1.5 × ULN. New York Heart Association classification I or II Squamous, small cell, or mixed histology. Known history of bleeding diathesis or coagulopathy. Cavitary tumors or tumors invading or abutting large blood vessels. Bleeding: Clinically significant bleeding such as gross hematuria, GI bleeding and hemoptysis within 12 months of Screening. Venous thromboembolic events within 6 months of screening. Ongoing therapy with oral or parenteral anticoagulants. Concurrent estrogens, antiestrogens or progesterone compounds. Radiotherapy within 2 weeks or major surgery within 4 weeks preceding Study Day 1. Symptomatic or clinically active brain metastases. Symptomatic coronary artery disease, cerebrovascular accident, transient ischemic attack, myocardial infarction or unstable angina pectoris within 6 months of screening. Grade 2 or higher peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>second-line</keyword>
	<keyword>lung cancer</keyword>
	<keyword>non small cell lung cancer</keyword>
	<keyword>bavituximab</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>